Virological Events During Immune Checkpoint Inhibitor Therapy: A Multi-Source Evaluation

Background/Objectives: Virological findings during immune checkpoint inhibitor (ICI) therapy may represent viral loss of control, pre-existing infection, tumour biomarkers, or infection after immune-related adverse event (irAE)-directed immunosuppression. Distinguishing these possibilities is important for treatment and diagnostic decisions. We evaluated virus-specific patterns across complementary data sources.